Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, National Research Council, Institute of Biomedicine and Molecular Biology, Reggio, Calabria, Italy.
Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, National Research Council, Institute of Biomedicine and Molecular Biology, Reggio, Calabria, Italy
Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1059-65. doi: 10.2215/CJN.11041013. Epub 2014 Apr 17.
Hyperuricemia predicts a high risk for CKD progression but there is no large clinical trial in humans indicating that this relationship is causal in nature. The rs734553 single-nucleotide polymorphism (SNP) of the GLUT9 urate transporter gene was strongly associated with uric acid (UA) levels in a large meta-analysis.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This prospective study adopted the Mendelian randomization approach. The rs734553 SNP was used as an instrumental variable to investigate the relationship between UA and renal outcomes in a cohort of 755 patients with CKD who were enrolled between October 18, 2005, and October 2, 2008. The association between the polymorphism and UA was preliminary confirmed in a series of 211 healthy volunteers enrolled between January 1, 2001, and July 12, 2011, from the same geographic area as the patients with CKD. The study end point was a composite renal-end point (i.e., >30% decrease in the GFR, dialysis, or transplantation). Patients were followed up for a median of 36 months.
In healthy individuals, serum UA levels were highest in homozygotes for the T allele (risk allele), intermediate in heterozygotes for the same allele, and lowest in those without the risk allele (P<0.001), but no such relationship was found in patients with CKD. In the CKD cohort, homozygotes (TT) and heterozygotes (GT) for the risk allele had a 2.35 times higher risk (hazard ratio, 2.35; 95% confidence interval, 1.25 to 4.42; P=0.008) of CKD progression. The risk for CKD progression by rs734553 remained unmodified in analyses adjusting for proteinuria, GFR, and other classical and CKD-peculiar risk factors.
A GLUT9 polymorphism, which is strongly associated with serum UA levels in healthy individuals of the general population with normal renal function, holds a strong predictive power for CKD progression. These findings are compatible with the hypothesis that the link between UA and CKD progression is causal in nature.
高尿酸血症预示着 CKD 进展的高风险,但目前尚无大型临床试验表明这种关系具有因果关系。在一项大型荟萃分析中,GLUT9 尿酸转运蛋白基因的 rs734553 单核苷酸多态性(SNP)与尿酸(UA)水平密切相关。
设计、地点、参与者和测量:本前瞻性研究采用孟德尔随机化方法。rs734553 SNP 被用作工具变量,以调查 755 例 CKD 患者队列中 UA 与肾脏结局之间的关系,这些患者于 2005 年 10 月 18 日至 2008 年 10 月 2 日入组。该多态性与 UA 的相关性在 2001 年 1 月 1 日至 2011 年 7 月 12 日期间从同一地理区域招募的 211 例健康志愿者的一系列研究中得到初步证实。研究终点是复合肾脏终点(即,GFR 下降>30%、透析或移植)。中位随访时间为 36 个月。
在健康个体中,携带 T 等位基因(风险等位基因)的纯合子血清 UA 水平最高,携带相同等位基因的杂合子血清 UA 水平居中,而不携带风险等位基因的个体血清 UA 水平最低(P<0.001),但在 CKD 患者中未发现这种关系。在 CKD 队列中,携带风险等位基因的纯合子(TT)和杂合子(GT)发生 CKD 进展的风险增加 2.35 倍(风险比,2.35;95%置信区间,1.25 至 4.42;P=0.008)。在调整蛋白尿、GFR 和其他经典及 CKD 特有的危险因素后,rs734553 对 CKD 进展的风险仍未改变。
在肾功能正常的一般人群中,与健康个体血清 UA 水平密切相关的 GLUT9 多态性对 CKD 进展具有很强的预测能力。这些发现与 UA 与 CKD 进展之间的因果关系假说一致。